Cullinan Therapeutics (CGEM) Total Liabilities (2020 - 2026)

Cullinan Therapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $36.8 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 32.22% year-over-year to $36.8 million; the TTM figure through Mar 2026 stood at $36.8 million (up 32.22% YoY), while the FY2025 annual figure was $39.6 million, up 25.87% from the prior year.
• Total Liabilities for Q1 2026 stood at $36.8 million, down from $39.6 million in the prior quarter.
• The five-year high for Total Liabilities was $62.6 million in Q2 2022, with the low at $18.0 million in Q1 2022.
• The 5-year median for Total Liabilities is $28.2 million (2025), against an average of $30.4 million.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities jumped 977.43% in 2022, then sank 64.22% in 2023.
• Cullinan Therapeutics' Total Liabilities stood at $26.1 million in 2022, then gained by 16.1% to $30.3 million in 2023, then climbed by 3.99% to $31.5 million in 2024, then advanced by 25.87% to $39.6 million in 2025, then fell by 7.14% to $36.8 million in 2026.
• Business Quant data shows CGEM's Total Liabilities at $36.8 million in Q1 2026, $39.6 million in Q4 2025, and $32.8 million in Q3 2025.